Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsIndependent Health Part D Prior Auth Coverage Upda…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentIndependent HealthPolicy N/A

    Prior Authorization and Coverage Criteria for Part D Formulary Specialty Drugs

    Customize your policy alerts

    Sign up for all Independent Health policy alerts

    Know when Independent Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization requirements and clinical criteria for outpatient prescription specialty drugs on Independent Health Medicare Advantage Part D formularies, including documentation, prescriber restrictions, testing requirements, coverage durations, and reauthorization rules.

    Policy Summary
    PayerIndependent Health
    PolicyPrior Authorization and Coverage Criteria for Part D Formulary Specialty Drugs
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJun 1, 2026
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization before dispensing any drug listed with 'PA' on the formularies.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    20+drugs listed in this excerpt
    1 yeartypical coverage duration
    Manyprescriber restrictions
    Mosttesting required

    Coverage Criteria (Product-Specific)

    ACTIMMUNE — Covered when specific documentation is provided

    Covered when specific documentation is provided

    ACTIMMUNE initial: Diagnosis of covered use for an FDA‑approved indication; submission of documentation describing how the drug will be used and/or obtained to determine Part B vs Part D coverage (e.g., whether medication will be self‑administered after training or will be filled at pharmacy and delivered to the office); coverage duration 1 year

    Prescriber and age per product labeling

    PAH/CTEPH agents (e.g., Adempas) — Covered when ALL of the following are met

    Covered when ALL of the following are met

    Hemodynamic confirmation: Diagnosis confirmed by right heart catheterization with documentation of WHO Group classification; mean pulmonary arterial pressure > 20 mm Hg at rest; pulmonary arterial wedge pressure ≤ 15 mm Hg; for PAH (WHO Group 1) PVR > 2 Woods units; for CTEPH PVR > 3 Woods units and imaging evidence of chronic pulmonary embolism with attestation disease is inoperable or persistent/recurrentmPAP > 20 mm Hg; PAWP ≤ 15 mm Hg; PVR thresholds as specified

    Provider Actions, Documentation & Prior Authorization

    Prior Authorization

    General prior authorization required

    Prior authorization is required for drugs on the formularies marked 'PA'; approval must be obtained before dispensing or the drug may not be covered.

    Prior Authorization

    AUSTEDO — tetrabenazine trial required

    For AUSTEDO (including AUSTEDO XR) initial authorization for Huntington's chorea requires that the patient tried and failed, or was intolerant to, tetrabenazine; prescriber specialty and exclusion criteria must also be satisfied.

    • Exclusion examples: congenital long QT syndrome, history of arrhythmia with prolonged QT, MAOI coadministration, active suicidal or untreated depression, hepatic impairment.
    • Coverage duration: 1 year; prescriber restrictions: neurology or psychiatry.
    Prior Authorization

    Product Codes and Key Clinical Values

    TRIKAFTA strengths/identifiersmixed
    50-75 & 150 MG, 50-25-37.5 & 75 MGStrengths listed for TRIKAFTA ORAL THERAPY PACK (dosage/packaging identifiers)
    Example productsNDC | description
    DUPIXENT SUBCUTANEOUS SOLUTION AUTO-INJECTORProduct listed
    DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 200 MG/1.14ML, 300 MG/2MLProduct listed
    GLP-1 agonists listedNDC | description
    MOUNJARO SUBCUTANEOUS SOLUTION AUTO-INJECTOR 10 MG/0.5ML, 12.5 MG/0.5ML, 15 MG/0.5ML, 2.5 MG/0.5ML, 5 MG/0.5ML, 7.5 MG/0.5MLProduct listed
    OZEMPIC SUBCUTANEOUS SOLUTION PEN-INJECTOR (various strengths)Product listed
    Covered products (examples)mixedCovered
    KISQALI (200 MG DOSE)Product listed in PA table
    KISQALI (400 MG DOSE)Product listed in PA table
    KISQALI (600 MG DOSE)Product listed in PA table
    Covered products (PARP inhibitor)mixedCovered
    LYNPARZA ORAL TABLETOlaparib product listed
    Products listedmixed
    miglustatlisted product name
    yargesalisted product name
    Products listedmixed
    MODEYSOlisted product name
    MYTESIlisted product name
    Products listedmixed
    NUCALA SUBCUTANEOUS SOLUTION AUTOINJECTORproduct presentation
    NUCALA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/MLproduct presentation
    NUCALA SUBCUTANEOUS SOLUTION RECONSTITUTEDproduct presentation

    Initial Therapy Criteria

    Continuation and Reauthorization Criteria

    Step Therapy and Prior Trials

    RequirementDetails
    Preferred-agent step requirement
    Initial authorization for many biologic/immunomodulatory drugs requires trial/failure or intolerance to at least two preferred agents (examples: adalimumab biosimilar, Cosentyx, Enbrel, Rinvoq, Skyrizi, ustekinumab biosimilar, Xeljanz/Xeljanz XR) where possible.
    RequirementDetails
    AUSTEDO prerequisite
    For treatment of chorea associated with Huntington's disease, initial authorization requires the patient tried and failed to have an adequate response to, or had intolerance/contraindication to, tetrabenazine.
    RequirementDetails
    AUVELITY step therapy
    For initial authorization the patient must have tried and failed to have an adequate response to or had intolerance to two generic on‑formulary antidepressants (e.g., bupropion, SSRI, SNRI).
    Product comparisonStep requirement
    Emgality (migraine prevention)
    Initial authorization requires prior trial and inadequate response or intolerance to Aimovig before Emgality.
    RequirementDetails
    CAMZYOS step requirement
    Initial authorization requires trial and inadequate response or intolerance/contraindication to both a beta‑blocker and a non‑dihydropyridine calcium channel blocker.
    ContextPrior therapy required
    Fabhalta — PNH
    For PNH: must have tried and failed or had intolerance/contraindication to eculizumab or ravulizumab (failure defined as hemoglobin <10 g/dL after 6 months on stable dose) prior to authorization.
    RequirementDetails
    INREBIC step therapy
    For initial authorization, the patient must have tried and failed to have an adequate response to or had intolerance/contraindication to ruxolitinib prior to INREBIC.

    Site of Care and Medicare Part B vs Part D Considerations

    Billing Rule

    Include Site‑of‑Care / Administration Details to Determine Part B vs Part D

    For PA submissions that could affect Part B vs Part D billing, include how the drug will be used/obtained and whether it will be self‑administered after training or supplied to the office by the patient, as coverage determination may depend on site‑of‑care.

    Note
    Note
    Note

    Exclusions, Contraindications & Denial Triggers

    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Background

    This document lists the clinical and administrative information required to support prior authorization (PA) requests for specialty and other Part D outpatient prescription drugs on Independent Health Medicare Advantage formularies. It explains that prior authorization is required for drugs designated with 'PA' on the formularies and that lack of PA may result in noncoverage, so providers must obtain approval before a prescription is filled (see contact information and formulary applicability).

    The policy defines the typical components of PA submissions: a confirmed diagnosis, required objective testing (for example, genetic or tumor testing, hemodynamic data, biopsy or histology, 24‑hour urine or blood biomarkers), baseline safety labs and physiologic measures (e.g., LFTs, electrolytes, creatinine clearance, QTc/QTcF), documentation of prior or concomitant therapies and reasons for failure or intolerance, prescriber specialty consistency, and patient age/ pregnancy status when applicable. Many drug entries also include specific exclusions (for example, pregnancy, moderate/severe hepatic impairment, or contraindicated drug interactions) and explicit coverage durations (commonly 1 year, with some initial shorter durations such as 6 months for selected products).

    Providers should follow the product‑specific criteria in this document when preparing PA requests — including the exact diagnostic confirmations, threshold values, prior‑therapy trials, and specialist prescriber requirements — because approvals are granted only when the documented evidence meets the stated criteria.

    Definitions and Clinical Thresholds

    Prior Authorization (PA)
    Prior Authorization (PA)An approval required from the payer before a prescription is filled; lack of approval may result in noncoverage.
    ImplicationDrugs listed with 'PA' require prior approval before dispensing; providers must submit required documentation to avoid denial
    ReferenceSee general PA requirement and denial risk statements in policy for specifics on required documents and prescriber restrictions
    Standard therapy (for biologics like Benlysta)
    Standard therapy (definition)Use of at least one of systemic corticosteroids, antimalarials, or immunosuppressants as part of baseline therapy
    ContextRequired as baseline therapy for initial BENLYSTA authorization and similar biologic indications
    Policy Summary
    PayerIndependent Health
    PolicyPrior Authorization and Coverage Criteria for Part D Formulary Specialty Drugs
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJun 1, 2026
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization before dispensing any drug listed with 'PA' on the formularies.
    SourceLink
    On This Page
    Coverage Criteria (Product-Specific)Provider Actions, Documentation & Prior AuthorizationProduct Codes and Key Clinical ValuesInitial Therapy CriteriaContinuation and Reauthorization CriteriaStep Therapy and Prior TrialsSite of Care and Medicare Part B vs Part D ConsiderationsExclusions, Contraindications & Denial TriggersBackgroundDefinitions and Clinical Thresholds

    Submit creatinine clearance (or data to calculate it) and pregnancy status for females of childbearing potential

    Age/prescriber and prior therapy: Patient is ≥18 years old; prescriber restricted to cardiology or pulmonology; for initial PAH (WHO Group 1) patient must have tried and had inadequate response to or been intolerant of both (1) sildenafil or tadalafil AND (2) ambrisentan or bosentan

    Coverage duration 1 year

    ALK-targeted agents (e.g., Alecensa, Alunbrig)

    Tumor testing and prescriber: Diagnosis of covered use with submission of test confirming ALK‑positive tumor; prescriber restricted to oncology; patient is ≥18 years; coverage duration 1 year

    Submit pregnancy status for females of childbearing potential

    Agent‑specific exclusion (Alunbrig): Exclude patients with uncontrolled hypertension

    Follow product labeling for other exclusions and interactions

    ARIKAYCE (MAC lung disease)

    Refractory MAC requirement: Diagnosis of Mycobacterium avium complex (MAC) lung disease that is refractory; documentation multi‑drug regimen (eg ethambutol, a macrolide, and a rifamycin) was tried for at least 6 months and sputum culture remains positive after that regimen

    Prescriber restricted to infectious disease or pulmonology; age ≥18; coverage duration 1 year

    ATTRUBY (transthyretin amyloid cardiomyopathy)

    Diagnostic confirmation for ATTR: Diagnosis of transthyretin amyloid cardiomyopathy confirmed by one of: (1) amyloid deposits on cardiac biopsy; (2) transthyretin precursor protein by immunohistochemistry; (3) technetium‑99 scintigraphy/SPECT consistent with ATTR; OR (4) TTR genetic mutation plus cardiac involvement (eg interventricular septal thickening)

    Prescriber restricted to cardiology; patient ≥18 years; coverage duration 1 year

    AUSTEDO (tardive dyskinesia / Huntington's chorea)

    Contraindications and exclusions: Exclude congenital long QT syndrome or history of arrhythmia with prolonged QT, coadministration with MAO inhibitors, active suicidal or untreated/undertreated depression, significant hepatic impairment; submit Child‑Pugh score where indicated

    Prescriber restricted to neurology/psychiatry; age ≥18

    Huntington's chorea prior therapy: For Huntington's disease chorea initial authorization requires trial and inadequate response to or intolerance of tetrabenazine

    Coverage duration 1 year

    Tardive dyskinesia reauthorization: Annual reauthorization requires confirmation of symptomatic or clinical improvement or maintenance of previously achieved improvement

    AUVELITY (depression)

    Exclusions: Exclude patients with seizure disorder, current/prior bulimia or anorexia nervosa, severe hepatic or renal impairment, recent MAOI use within 14 days; require bipolar disorder screening attestation

    Prescriber restricted to psychiatry; age ≥18

    Prior therapy requirement: Initial authorization requires failure or intolerance to two generic on‑formulary antidepressants (eg SSRI, SNRI, bupropion)

    Coverage duration 1 year

    AYVAKIT

    Drug interactions and platelet exclusion: Exclude coadministration with moderate/strong CYP3A inducers or inhibitors; for advanced/indolent systemic mastocytosis exclude platelet count <50 x10^9/Lplatelets <50 x10^9/L (exclude)

    Prescriber restricted to allergy/hematology/immunology/oncology; age ≥18

    Tumor‑specific testing: For gastrointestinal stromal tumor (GIST) submit PDGFRA exon 18 mutation result; submit pregnancy status for females of childbearing potential

    Coverage duration 1 year

    BALVERSA (FGFR3-altered bladder cancer)

    Prior therapy and molecular testing: Diagnosis of covered use with submission of test confirming susceptible FGFR3 genetic alteration; documentation of current/previous therapies; exclude patients eligible for but not treated with PD‑1/PD‑L1 therapy

    Prescriber restricted to oncology; age ≥18; coverage duration 1 year

    NEXLETOL / NEXLIZET

    Prior lipid therapy requirement: For initial authorization: either (1) current statin use (unless contraindicated) plus ezetimibe; OR (2) trial and inadequate response or intolerance to at least two statins OR one statin plus ezetimibe; at least one previously tried statin must be hydrophilic; submit prior lipid‑lowering therapy documentation

    Annual reauthorization requires continued use of prior lipid‑lowering therapies unless new contraindication; coverage duration 1 year

    BENLYSTA (systemic lupus erythematosus)

    Baseline therapy requirement: Patient must be using standard therapy (systemic corticosteroid, antimalarial, or immunosuppressant) at baseline; submit ANA and/or anti‑dsDNA positivity for SLE; prescriber restricted to immunology/nephrology/rheumatology

    Annual reauthorization requires continued use of some form of standard therapy unless contraindicated; coverage duration 1 year

    Diagnostic lab: Submit autoantibody‑positive test result (ANA and/or anti‑dsDNA) for SLE when applicable

    BESREMI

    Exclusions and prior therapy: Exclude severe psychiatric disorders, active untreated autoimmune disease, moderate‑severe hepatic impairment (Child‑Pugh B/C), immunosuppressed transplant recipients, unstable CV disease, recent stroke/MI; require eGFR and documentation of trial/failure or intolerance to hydroxyurea if applicable

    Prescriber restricted to hematology/oncology; coverage duration varies with hydroxyurea use

    Topical/systemic immunomodulators (class rule)

    TB screening and step requirement: For drugs managed by this policy (except Otezla and Velsipity) submit baseline latent TB screening (PPD or IGRA); if positive, treat latent TB before coverage; initial authorization generally requires prior failure of at least two preferred agents where possible

    Coverage duration 1 year

    BOSULIF (CML)

    Accelerated/blast phase Ph+ CML: For accelerated or blast phase Ph+ CML initial authorization requires either (1) intolerance to dasatinib, imatinib, or nilotinib OR (2) imatinib resistance meeting defined hematologic/cytogenetic failure criteria; prescriber restricted to hematology/oncology

    Coverage duration 1 year

    BRAFTOVI + MEKTOVI (BRAF V600E/K melanoma and others)

    BRAF mutation and coadministration: Require test confirming BRAF V600E (or V600K for melanoma); for certain indications require confirmation companion agents will be coadministered (eg encorafenib + binimetinib for melanoma; encorafenib + cetuximab for colorectal cancer)

    Prescriber restricted to oncology; age ≥18; coverage duration 1 year

    Butalbital-containing products (older patients)

    Age restriction and alternatives: Prior authorization applies to patients ≥65 years old; require documentation patient tried and failed a preferred alternative (eg ibuprofen or rizatriptan) or has contraindications to all alternativesage >= 65

    Coverage duration 1 year

    BYLVAY (cholestatic liver diseases)

    Genetic and cholestasis documentation: Diagnosis confirmed by molecular genetic testing AND documentation of cholestasis via one of: age‑adjusted elevated total serum bile acids, increased conjugated bilirubin, GGT > ULN, fat‑soluble vitamin deficiency, or intractable pruritus attributable to liver disease; attestation drug‑induced pruritus ruled out; prior trial/failure or intolerance to at least two of cholestyramine, naltrexone, rifampin, ursodiol

    Exclude decompensated cirrhosis; prescriber restricted to gastroenterology/hepatology; initial coverage 6 months then 1 year; reauthorization requires pruritus improvement and LFTs including bilirubin

    CABLIVI – Initial and reauthorization criteria

    CABLIVI: Covered when ALL of the following are met

    CABLIVI initial authorization: Diagnosis of covered use; confirmation drug will be given with plasma exchange and immunosuppressive therapy; if not first use submit prior aTTP recurrences while on caplacizumab

    Age ≥12 years; prescriber restricted to cardiology/hematology/immunology; coverage duration 3 months; not authorized if >2 recurrences while on therapy

    CAPLACIZUMAB – Authorization

    Caplacizumab (CABOMETYX entry): Covered when ALL of the following are met

    Caplacizumab authorization: Diagnosis of covered use; confirm drug administered with plasma exchange and immunosuppressive therapy; age ≥12 years; prescriber restricted to cardiology/hematology/immunology

    Coverage duration 3 months; if not first use submit prior recurrence history; coverage not authorized if patient has had >2 recurrences while on therapy

    CFTR modulators – Mutation-confirmed authorization

    CFTR modulators (Kalydeco/Orkambi/Symdeko/Trikafta): Covered when ALL of the following are met

    CFTR modulators authorization: Diagnosis of covered use; submission of CFTR mutation test confirming presence of mutations as specified per requested drug (eg ivacaftor‑responsive mutations for Kalydeco; two F508del copies for Orkambi; Trikafta requires at least one responsive mutation per prescribing info or in‑vitro data); prescriber restricted to pulmonology

    Coverage duration 1 year; coadministration with strong CYP3A inducers excluded; Trikafta excludes severe hepatic impairment

    DOPTELET – Procedural and ITP criteria

    DOPTELET: Covered when ALL of the following are met (separate logic for procedural vs ITP use)

    DOPTELET procedural use: Diagnosis thrombocytopenia in chronic liver disease scheduled for procedure AND platelet count <50 x10^9/Lplatelets <50 x10^9/L

    Coverage duration 5 days; prescriber restricted to gastroenterology/hepatology/surgery

    DOPTELET ITP initial authorization: Diagnosis of immune thrombocytopenia (ITP) with platelet count <30 x10^9/L OR <50 x10^9/L with symptomatic bleeding AND patient has undergone splenectomy OR tried and failed at least two ITP therapies from different classes (systemic corticosteroids, IVIG, danazol, fostamatinib, cytotoxics/immunosuppressants including rituximab)

    Initial coverage 2 months then 1 year; first reauthorization requires platelet ≥50 x10^9/L after ≥4 weeks on max tolerated dose; annual reauthorization requires maintenance of benefit

    Dupixent – Indication-specific criteria

    Dupixent: Covered when ALL of the following are met (criteria vary by indication)

    Asthma indication: Diagnosis of covered asthma; pre‑bronchodilator FEV1 <80% predicted (or <90% in children) AND either blood eosinophils ≥150 cells/mcL within 6 weeks of initiation OR asthma requiring daily oral corticosteroid for control; submit current/previous therapies; prescriber restricted to allowed specialtieseos ≥150 cells/mcL within 6 weeks or daily OCS dependence

    Initial authorization 6 months then 1 year; provider must attest continuation of background therapy

    COPD indication: Diagnosis of covered COPD; post‑bronchodilator FEV1/FVC <0.7 AND post‑bronchodilator FEV1 30%–80% predicted AND blood eosinophils ≥300 cells/mcL within 6 weeks AND symptomatic disease; submit current/previous therapieseos ≥300 cells/mcL

    Prescriber restrictions apply

    CRSwNP indication: Diagnosis with evidence of nasal polyps AND attestation of symptomatic nasal congestion; submit prior therapies

    Intranasal corticosteroid trial generally required prior to biologic

    EoE indication: Upper endoscopy with biopsy showing ≥15 eos/high‑power field (or 60 eos/mm2) AND symptoms consistent with EoE AND trial and failure of at least an 8‑week PPI course; age restriction ≥11 years; coverage duration 12 weeks; max one 12‑week course per 365 dayshistology threshold

    Prescriber restricted to allergy/gastroenterology/immunology/ENT

    Prurigo nodularis (PN): Documentation of pruritus ≥6 weeks AND presence of pruriginous firm nodular lesions; submit prior therapies

    Prescriber restricted to dermatology/allergy/etc.

    Initial Therapy (Dupilumab)

    Dupilumab — Covered when ALL of the following are met:

    Dupilumab initial authorization: Patient meets indication‑specific diagnostic requirements (AD, asthma, COPD, CRSwNP, PN, EoE) AND has trialed/failed specified prior therapies per indication (eg topical corticosteroid for AD; guideline‑based inhaler regimen for asthma; intranasal corticosteroid for CRSwNP) OR has documented contraindication to those therapiessee indication sections

    Provider must attest continuation of background therapy where required

    Reauthorization (Dupilumab)

    Dupilumab — Reauthorization requirements:

    Dupilumab reauthorization: For asthma/COPD: confirm patient remains on required background therapy (eg triple inhaler) AND provide documentation of clinical benefit (reduced exacerbations, steroid dose, or improved FEV1) or maintenance of prior benefit. For CRSwNP/AD/PN/EoE: documentation of clinical benefit or maintenance of benefit is requiredclinical benefit measures as applicable

    Reauthorization intervals typically annually after initial period

    Reauthorization timing: Initial authorization typically 6 months then annual renewal; provide required objective measures per indication

    Eltrombopag ITP

    Eltrombopag — Covered when ALL of the following are met for ITP:

    Eltrombopag ITP initial authorization: Platelet count <30 x10^9/L OR <50 x10^9/L with increased bleeding risk; documentation patient has undergone splenectomy OR tried and failed at least two different ITP therapies from different classes (systemic corticosteroids, IVIG, danazol, fostamatinib, cytotoxics/immunosuppressants such as rituximab); submit platelet counts and prior therapy historyplatelet thresholds as stated

    First reauthorization requires updated platelet count showing improvement; coverage durations per indication

    EoE

    Eohilia/EoE — Covered when ALL of the following are met:

    EoE initial authorization: Upper endoscopy with biopsy showing ≥15 eosinophils per high‑power field (or 60 eos/mm2) AND signs/symptoms consistent with EoE AND trial and failure of at least an 8‑week proton pump inhibitor course to exclude GERD‑related eosinophiliahistology threshold

    Age restriction ≥11 years; coverage duration 12 weeks; maximum one 12‑week course every 365 days

    Fabhalta PNH

    Fabhalta (PNH, IgAN, C3G) — Initial authorization criteria:

    Fabhalta — PNH: For paroxysmal nocturnal hemoglobinuria (PNH): flow cytometry confirming PNH clones AND objective signs attributable to PNH (eg hemoglobin <10 g/dL, LDH >1.5x ULN, hemosiderinuria, thrombosis) AND patient has tried and failed or is intolerant/contraindicated to eculizumab or ravulizumab (failure defined as Hb <10 g/dL after 6 months on stable dose)

    Prescriber restricted to hematology; reauthorization requires confirmation of symptomatic/clinical improvement or maintenance

    GLP-1 and related diabetes products

    Covered when ALL of the following are met (example: GLP-1 agents listed)

    GLP‑1 product coverage: Diagnosis of type 2 diabetes confirmed by medical record, ICD‑10 claim, or laboratory evidence (A1c, fasting glucose, 2‑hr OGTT, or random glucose with symptoms); age consistent with product labeling; prescriber consistent with product labeling; documentation that request is not for weight management (off‑label use excluded under Medicare Part D)

    Coverage duration 1 year; applies to Mounjaro, Ozempic, Rybelsus, Trulicity, etc.

    Hereditary angioedema prophylaxis

    Covered when ALL of the following are met (example: HAE prophylaxis agents)

    HAE prophylaxis: Diagnosis of hereditary angioedema requiring prophylaxis with objective documentation of disease activity, attack frequency, and impact on quality of life; prescriber restricted to allergy/dermatology/hematology/immunology; age per labeling; coverage duration 1 year

    Requests for acute HAE attack treatment are excluded

    Oncology targeted therapies

    Covered when ALL of the following are met (oncology-targeted agents)

    Oncology targeted therapy criteria: Diagnosis of covered indication; submission of tumor/genetic testing confirming the required biomarker (eg HER2, ROS1, PIK3CA, FGFR, MET exon 14 skipping, EGFR mutations) as applicable; pregnancy status for females of childbearing potential; prescriber restricted to oncology; age ≥18; coverage duration 1 year

    Some agents additionally require prior systemic therapy failure or specified prior lines of therapy

    Immune globulins

    Covered when ALL of the following are met (immune globulin products)

    IV/SC immune globulins: Diagnosis of covered use with indication‑specific laboratory data (eg platelet count for ITP; IgG <600 mg/dL and infection history for CLL; unequivocal CIDP diagnosis with corticosteroid failure/intolerance); coverage duration: acute conditions 3 months, chronic conditions 1 year; reauthorization requires documentation of clinical benefit

    IV formulations may be covered as Part B if administered in the home for primary immune deficiency; site of care may affect Part B vs Part D determination

    JUXTAPID (lomitapide) coverage

    Covered when ALL of the following are met (JUXTAPID)

    JUXTAPID criteria: Diagnosis consistent with homozygous familial hypercholesterolemia with at least one of: functional mutations in both LDL receptor alleles OR skin fibroblast LDL receptor activity <20% OR untreated total cholesterol >500 mg/dL with triglycerides <300 mg/dL and parental TC >250 mg/dL; submit baseline LFTs, LDL‑C, TC, apoB, non‑HDL‑C and pregnancy status; prescriber restricted to cardiology/lipidology/endocrinology experienced in lipid management; initial duration 6 months then 1 year; initial auth in patients ≥10 years requires prior trial/failure/intolerance to evolocumab

    Reauthorization requires LDL reduction from baseline and documented ongoing benefit

    KERENDIA (finerenone) coverage

    Covered when ALL of the following are met (KERENDIA)

    KERENDIA criteria: Diagnosis of covered use; submit eGFR and baseline serum potassium; patient ≥18; exclude adrenal insufficiency, eGFR <25 mL/min/1.73 m2, baseline serum potassium >5.0 mEq/L, severe hepatic impairment; initial authorization requires trial/failure or intolerance to Farxiga or Jardiance; coverage duration 1 yeareGFR <25 mL/min/1.73 m2 (exclusion); serum potassium >5.0 mEq/L (exclusion)

    Reauthorization requires documented maintenance or improvement

    KOMZIFTI — Initial Authorization

    Covered when ALL of the following are met

    KOMZIFTI initial authorization: Patient ≥18; diagnosis corresponds to FDA‑approved indication; genetic tumor testing confirms primary tumor is HR‑positive, HER2‑negative; baseline QTcF, potassium and magnesium within previous 6 months submitted; pregnancy status for females of childbearing potential; prescriber restricted to oncology; coverage duration 1 yearQTcF <450 msec generally; see exclusions

    Coadministration cautions: congenital long QT syndrome, QTcF ≥450 msec, uncorrected hypokalemia/hypomagnesemia, strong CYP3A4 inducers or QT‑prolonging drugs are exclusionary

    KRAZATI — Authorization

    Covered when ALL of the following are met

    KRAZATI authorization: Patient ≥18; test confirms KRAS G12C mutation; for NSCLC document at least one prior therapy tried and failed; for colorectal cancer document prior fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy; prescriber restricted to oncology; coverage duration 1 year

    Exclude congenital long QT syndrome or coadministration with strong CYP3A4 inducers or QT‑prolonging drugs

    LYNPARZA — Authorization

    Covered when ALL of the following are met

    LYNPARZA (olaparib) authorization: Patient ≥18; diagnosis matches FDA‑approved indication; submit BRCA and/or homologous recombination repair mutation testing as required per indication; meet indication‑specific attestations (eg response to platinum chemo for ovarian cancer); prescriber restricted to oncology/urology where specified; coverage duration 1 year; coadministration with moderate/strong CYP3A inducers excluded

    l-glutamine — Initial Authorization

    Covered when ALL of the following are met

    l‑glutamine initial authorization: Diagnosis of sickle cell disease; documentation of current or previous therapies; for initial authorization patient must have used, tried and failed to have an adequate response to, or had intolerance/contraindication to hydroxyurea; prescriber restricted to hematology; coverage duration 1 year

    Submit prior therapy details

    MAVYRET — Authorization

    Covered when ALL of the following are met

    MAVYRET authorization: Laboratory confirmation of HCV infection and genotype; exclude moderate/severe hepatic impairment (Child‑Pugh B/C) and coadministration with rifampin or atazanavir; coverage duration consistent with AASLD‑IDSA guidance

    No prerequisite therapy required

    Initial therapy - eosinophil-targeted biologics

    Covered when ALL of the following are met for mepolizumab and other eosinophil-targeted biologics:

    Eosinophil‑targeted biologics initial: Diagnosis matches FDA‑approved indication (asthma, COPD, CRSwNP, EGPA, HES) AND meets indication‑specific objective criteria (eg asthma: FEV1 and blood eosinophil thresholds — blood eos ≥150 cells/mcL within 6 weeks or ≥300 cells/mcL within 12 months; COPD: post‑BD FEV1/FVC <0.7 and FEV1 30–80% plus eosinophil thresholds; CRSwNP: evidence of nasal polyps and symptomatic nasal congestion; EGPA: eos% ≥10% or absolute eos ≥1000 cells/mm3; HES: uncontrolled disease with ≥2 flares in past 12 months and eos ≥1000 cells/mcL); prescriber restricted to allowed specialtiesblood eos thresholds per indication

    Provider must attest continuation of background therapy (eg triple inhaler) where specified

    Reauthorization criteria (eosinophil-targeted biologics)

    Reauthorization requirements (annual):

    Annual reauthorization: Submission of documentation showing clinical improvement or maintenance of prior benefit (examples: reduced exacerbations, reduced systemic steroid dose, improved FEV1, reduced nasal polyp score) and updated labs or scores where required; for asthma/COPD reauth confirm continued background therapy (eg triple inhaler)clinical benefit or maintenance

    Coverage typically renewed for 1 year

    Prerequisite therapy

    Step therapy / prerequisite therapy for select drugs:

    Inbrija prerequisite therapy: Attestation patient experiences 'off' episodes despite carbidopa/levodopa AND prior trial/failure/intolerance of at least two different classes (COMT inhibitors, dopamine agonists, MAO‑B inhibitors) unless contraindicated; prescriber restricted to neurologytrial of >=2 classes

    Annual reauthorization requires confirmation of clinical improvement

    Sodium oxybate prerequisite: Diagnosis confirmed by sleep study; prior failure/intolerance to armodafinil or modafinil AND solriamfetol required for adults with narcolepsy excessive daytime sleepinessprior failures of 2 agents

    Prescriber restricted to neurology/psychiatry/sleep medicine; age >=7 for sodium oxybate

    Testing and organ function criteria

    Genetic/mutation and organ function prerequisites for oncology and other specialty products:

    Genetic testing requirement: Products require submission of specific tumor/genetic testing results as applicable (eg H3K27M, BRCA, FGFR, FLT3, EGFR, MET exon 14, PIK3CA) confirming the required alteration for the requested indicationtest confirming mutation/fusion

    If testing negative, documentation of intolerance/contraindication to alternatives may be required

    Organ function and safety testing: When indicated submit liver function tests or Child‑Pugh score for hepatic impairment and creatinine clearance or eGFR for renal function; moderate/severe hepatic impairment often exclusionary (Child‑Pugh B/C)Child‑Pugh/CrCl values as specified

    Coadministration with certain CYP or P‑gp inhibitors/inducers may be exclusionary

    Kaposi sarcoma related agents

    Covered when the following requirements specific to the drug are met:

    Kaposi sarcoma agents: Adult patient (≥18), not pregnant, prescriber restricted to dermatology or oncology, and absence of criteria requiring systemic Kaposi sarcoma therapy (eg >10 new lesions/month, symptomatic lymphedema, symptomatic pulmonary or visceral involvement)

    Coverage duration 1 year

    Inbrija (levodopa inhalation) criteria

    Covered when ALL of the following are met for Inbrija:

    Inbrija initial authorization: Diagnosis of Parkinson's 'off' episodes despite carbidopa/levodopa; patient ≥18; attestation of trials/failures/intolerance to at least two medication classes that reduce off episodes (COMT inhibitors, dopamine agonists, MAO‑B inhibitors) unless contraindicated; prescriber restricted to neurology; exclude recent non‑selective MAOI use within 14 days and underlying asthma/COPD or other chronic lung disease

    Coverage duration 1 year; annual reauthorization requires confirmation of symptomatic/clinical improvement or maintenance

    PEMAZYRE criteria

    Covered when ALL of the following are met for PEMAZYRE:

    PEMAZYRE initial: Diagnosis of covered indication; submission of test confirming FGFR1 rearrangement or FGFR2 fusion/rearrangement as applicable; attestation patient has used previous systemic treatment for the indication; prescriber restricted to hematology/oncology; submit pregnancy status for females of childbearing potential; coadministration with moderate/strong CYP3A4 inducers excluded

    Coverage duration 1 year

    REPATHA coverage criteria

    Covered when criteria for the specific indication are satisfied:

    REPATHA initial for MACE or HeFH: Patient ≥10; tried and failed to achieve LDL <70 mg/dL despite ≥8 weeks high‑intensity statin therapy OR experienced statin‑associated rhabdomyolysis OR documented intolerance to atorvastatin and rosuvastatin; prescriber restricted to cardiology/endocrinology or lipid specialists; coverage duration 1 yearLDL <70 mg/dL target failure

    Indication‑specific documentation required

    REPATHA HoFH: For homozygous familial hypercholesterolemia follow similar statin failure/intolerance documentation as above and other HoFH diagnostic criteria

    Coverage duration 1 year

    RECORLEV criteria

    Covered when ALL of the following are met for RECORLEV:

    RECORLEV initial: Diagnosis of Cushing's syndrome; 24‑hour urine free cortisol (UFC) baseline >1.5× ULN (>50 µg or 145 nmol); attestation pituitary surgery is not an option or not curative; ECG including QTcF and liver function tests within 3 months; patient tried and failed at least one other therapy (eg mifepristone, pasireotide); prescriber restricted to endocrinology24‑hour UFC >1.5× ULN

    Coverage duration 1 year; exclusion: severe hepatic impairment (Child‑Pugh C) and certain QT‑related conditions; reauthorization requires clinically relevant response or maintenance

    REVUFORJ initial therapy

    Covered when ALL of the following are met:

    REVUFORJ initial criteria: Diagnosis of covered use AND test confirming KMT2A translocation (not 11q23 PTD) or absence of susceptible NPM1 mutation; submission of baseline QTcF, serum potassium, serum magnesium, baseline WBC, and pregnancy status; prescriber restricted to hematology/oncology; coverage duration 1 yearsee documentation

    QT/electrolyte monitoring required; exclusions apply

    RIVFLOZA initial therapy

    Covered when ALL of the following are met:

    RIVFLOZA initial criteria: Diagnosis of primary hyperoxaluria with AGXT mutation confirmed by enzyme analysis or genetic testing; 24‑hour urinary oxalate (Uox) ≥0.7 mmol (normalized if <18); submit eGFR and attest no prior kidney/liver transplant and not using lumasiran; prescriber restricted to nephrology/urology; initial coverage 6 months then 1 yearUox ≥0.7 mmol

    First reauthorization requires evidence of response (reduced Uox or plasma oxalate)

    Atypical antipsychotics criteria

    Covered when ALL of the following are met for certain psychiatric indications:

    Atypical antipsychotics criteria: Diagnosis of schizophrenia or bipolar/major depressive disorder per indication; submission of current/previous therapies and required trials/failures (eg failure/intolerance to aripiprazole and one other generic second‑generation atypical for schizophrenia; other indication‑specific trials for adjunctive depression), prescriber restricted to psychiatry; coverage duration 1 yearsee Other Criteria

    Step therapy requirements apply

    Sedative-hypnotics (older adults)

    Covered when ALL of the following are met for sedative-hypnotic approvals in older adults:

    Sedative‑hypnotics (>=65): Patient is ≥65 years AND documentation that at least two alternatives (Belsomra, doxepin, ramelteon, trazodone) were tried and ineffective/intolerableage >= 65

    PA applies only to patients 65 and older; coverage duration 1 year

    BPH product — initial authorization

    Covered when ALL of the following are met for the listed BPH product(s):

    BPH product initial criteria: Diagnosis of benign prostatic hyperplasia; submission of creatinine clearance (or serum creatinine, weight, height to calculate); patient ≥18; prescriber restricted to urology; coverage duration 1 year

    Annual reauthorization requires confirmation of symptomatic/clinical improvement; erectile dysfunction indication excluded

    ATTR cardiomyopathy — initial authorization

    Covered when ALL of the following are met for transthyretin amyloid cardiomyopathy products:

    ATTR cardiomyopathy initial criteria: Diagnosis of ATTR (wild‑type or hereditary) confirmed by cardiac biopsy with amyloid, transthyretin by immunohistochemistry, technetium‑99 scintigraphy/SPECT, or TTR mutation plus cardiac involvement (interventricular septal thickening); patient ≥18; prescriber restricted to cardiology; coverage duration 1 year

    No prerequisite therapy required

    Oncology molecularly-targeted agents — initial authorization

    Covered when ALL of the following are met for oncology-targeted therapies requiring mutation testing:

    Oncology molecularly‑targeted agents: Diagnosis of the covered indication; submission of tumor molecular/genetic testing confirming the required mutation/fusion (eg EGFR, MET exon 14 skipping, PIK3CA/AKT1/PTEN, HER2, IDH1) as applicable; pregnancy status for females of childbearing potential; prescriber restricted to oncology; coverage duration 1 year

    Some products additionally require prior therapy (eg prior endocrine regimen, prior chemotherapy) as specified per product

    Parathyroid hormone analogs — initial and continuation

    Covered when ALL of the following are met for parathyroid hormone analogs (osteoporosis):

    Parathyroid hormone analog criteria: Diagnosis meeting 'high risk for fracture' definition (history of hip or vertebral fracture OR specified T‑score/fracture combinations or FRAX thresholds); submission of baseline serum calcium and prior therapy details; initial authorization requires trial/failure or intolerance to at least one bisphosphonate (failure = fracture or BMD decrease while on bisphosphonate ≥3 months); coverage typically 2 yearsFRAX/ T‑score criteria as defined

    Annual reauthorization beyond 2 years requires updated serum calcium and evidence patient remains high risk

    Tolvaptan — ADPKD and hyponatremia formulations

    Covered when ALL of the following are met for tolvaptan formulations:

    Tolvaptan ADPKD criteria: For ADPKD formulation: diagnosis of rapidly progressing ADPKD (Mayo class 1C–1E OR historical eGFR decline ≥3 mL/min/1.73 m2/year over 4 years OR PROPKD score >6); submission of serum sodium; prescriber restricted to nephrology; coverage 1 year; reauthorization requires confirmation of clinical benefit or maintenance

    Certain tolvaptan formulations (hyponatremia formulation) are limited and NOT approved for ADPKD

    Tolvaptan hyponatremia criteria: For hyponatremia formulation: clinically significant hyponatremia defined as serum sodium <125 mEq/L OR symptomatic serum sodium <135 mEq/L resistant to fluid restriction; exclude underlying liver disease; treatment initiated where sodium can be closely monitored; coverage limited to 30 days to prevent liver injuryserum sodium thresholds as stated

    This formulation will not be approved for ADPKD

    Vanrafia — IgA nephropathy

    Covered when ALL of the following are met for VANRAFIA (IgA nephropathy):

    IgA nephropathy criteria: Primary IgA nephropathy confirmed by renal biopsy; submission of 24‑hour urine protein ≥0.5 g/day OR UPCR ≥0.8 g/g; submission of current/prior therapies; prescriber restricted to immunology or nephrology; patient must be using (or intolerant/contraindicated to) maximally tolerated ACE inhibitor or ARB prior to initiation; coverage duration 1 year; annual reauthorization requires documentation of clinically relevant response (stabilization or improvement of UPCR or reduction in 24‑hour urine protein)proteinuria thresholds as stated

    Submit liver function testing/Child‑Pugh if indicated

    Verquvo — HFrEF

    Covered when ALL of the following are met for verquvo (sGC stimulator):

    Verquvo HFrEF criteria: Diagnosis includes hospitalization for HFrEF within previous 6 months OR outpatient IV diuretic use within previous 3 months; submit LVEF <45%; patient ≥18; prescriber restricted to cardiology; patient must be on ACEi/ARB/sacubitril‑valsartan, a beta‑blocker, and an MRA each at maximally‑tolerated doses or provide documentation why not; submit pregnancy status; exclude concomitant use of another sGC stimulator or a PDE‑5 inhibitorLVEF <45%

    Coverage duration 1 year; annual reauthorization requires demonstration of clinical benefit or maintenance

    Initial Therapy — Vasomotor symptoms product

    Covered when ALL of the following are met for the vasomotor symptoms product:

    Vasomotor symptoms coverage criteria: Diagnosis of vasomotor symptoms due to menopause; patient tried and failed or intolerant to at least two prior systemic hormone therapies OR FDA‑approved/compendia non‑hormonal therapies from different classes; submit eGFR and LFTs; exclude coadministration with CYP1A2 inhibitors, severe renal impairment/ESRD, known cirrhosis, or aminotransferases/total bilirubin ≥2× ULN; coverage duration 1 year; reauthorization requires documented improvement or maintenance

    Drugs tried must be from different medication classes

    Initial Therapy — PIK3CA-targeted product

    Covered when ALL of the following are met for the PIK3CA-targeted product:

    PIK3CA product criteria: Diagnosis with at least one target lesion on imaging and provider attestation of severe or life‑threatening disease; submit test confirming PIK3CA mutation; pregnancy status for females of childbearing potential; prescriber restricted to specialists in genetic diseases/inborn errors of metabolism; initial coverage 6 months then 1 year; reauthorization requires objective documentation of symptomatic or clinical benefit or maintenancemutation confirmed

    Initial Therapy — IgA nephropathy

    Covered when ALL of the following are met for IgA nephropathy (VOYXACT):

    IgAN coverage criteria: Primary IgA nephropathy confirmed by biopsy; 24‑hour urine protein ≥0.5 g/day OR UPCR ≥0.8 g/g; prescriber restricted to immunology or nephrology; patient must have tried and failed or been intolerant to both (1) maximally‑tolerated ACE inhibitor or ARB AND (2) atrasentan or sparsentan prior to initiation; coverage duration 1 year; annual reauthorization requires documentation of clinically relevant response (stabilization or improvement of UPCR or reduction in 24‑hour urine protein)proteinuria thresholds

    Biopsy confirmation required

    XIFAXAN coverage criteria

    Covered when ALL of the following are met for Xifaxan (rifaximin) 550 mg:

    Xifaxan — HE: Hepatic encephalopathy (HE): patient tried and failed or intolerant to lactulose; coverage for HE: 1 year

    Prescriber restricted to gastroenterology/hepatology

    Xifaxan — IBS‑D: IBS‑D: patient tried and failed at least two medication classes (antidiarrheals, antispasmodics, tricyclic antidepressants); coverage: 14 days per course with maximum three 14‑day courses per lifetimecourse limits as stated

    Documentation of prior therapies required

    Xifaxan — SIBO: SIBO: positive carbohydrate breath test AND documentation of prior antibiotic trials (at least two other antibiotics with efficacy) and prior rifaximin course history within previous 365 days; coverage: 14 days per course with maximum two 14‑day courses per 365 dayscourse limits as stated

    Submit dates of prior rifaximin courses and breath test results

    Wegovy (non-weight-management) coverage

    Covered when ALL of the following are met for Wegovy indications included here (non-weight-management uses such as MACE or MASH):

    Wegovy — MACE indication: Documentation patient has established cardiovascular disease (prior MI, prior stroke, or symptomatic PAD defined by intermittent claudication with ABI <0.85 at rest, prior peripheral revascularization, or amputation for atherosclerotic disease); BMI ≥25 kg/m2; attestation patient is not using semaglutide for diabetes and not receiving another GLP‑1 agonist; submit current cardiovascular risk regimen; prescriber restricted to cardiology/gastroenterology/hepatology/primary care; initial 32 weeks then 1 year; reauthorization requires updated CV regimen and documentation of clinical benefit or maintenanceBMI ≥25 kg/m2

    Weight management use excluded under Medicare Part D

    Wegovy — MASH indication: Confirmation of F2–F3 fibrosis by biopsy, MRE, or vibration‑controlled elastography; submit baseline liver tests/Child‑Pugh; first reauth requires documentation of improvement or stabilization of fibrosis; annual reauth requires maintenance of benefitF2–F3 fibrosis required

    Coverage not approved for weight management under Part D

    XOLAIR coverage criteria

    Covered when ALL of the following are met for omalizumab (Xolair):

    Xolair — asthma initial: Diagnosis appropriate to FDA‑approved asthma indication; patient on GINA‑recommended regimen (maximally‑tolerated ICS + LABA + LAMA) prior to biologic and prescriber attests therapy will be continued after starting Xolair; submit pre‑treatment weight, serum IgE (30–700 IU/mL for patients ≥12 where specified), positive skin test or in‑vitro reactivity to perennial aeroallergen, and pre‑bronchodilator FEV1 <80% predicted (<90% in children); prescriber restricted to specified specialtiesIgE 30–700 IU/mL where specified

    Initial coverage 6 months then 1 year; reauthorization requires documented clinical benefit or maintenance

    Xolair — CRSwNP: Evidence of nasal polyps and symptomatic nasal congestion; pre‑treatment serum IgE ≥30 IU/mL where specified; trial of intranasal corticosteroid ≥2 months or documentation why not advisable; prescriber restricted to specified specialties; reauthorization requires clinical benefit or maintenanceintranasal steroid >=2 months
    Xolair — CSU: Trial of at least 30 days of oral antihistamine without sufficient control; reauthorization requires documentation of clinical benefit or maintenance>=30 days antihistamine trial

    Initial and Reauthorization Criteria (selected examples)

    Reauthorization and initial authorization requirements summarized for listed indications

    Asthma initial & reauth summary: Initial: patient must be on maximally‑tolerated ICS+LABA+LAMA per GINA prior to biologic and provider must attest continuation. Reauth: confirm continued background therapy and documentation of clinical benefit (eg reduced exacerbations, steroid use, improved FEV1) or maintenance of prior benefit

    Applies to asthma biologics including omalizumab

    CRSwNP initial & reauth summary: Initial: intranasal corticosteroid trial ≥2 months (or documented contraindication). Reauth: confirmation of continued intranasal corticosteroid use and clinical benefit or maintenance
    CSU initial & reauth summary: Initial: trial of ≥30 days oral antihistamine with continued severe symptoms. Reauth: documentation of clinical benefit or maintenance

    CABLIVI — PA and reauthorization documentation

    CABLIVI initial authorization is limited (initial 6 months then 1 year) and requires documented cholestasis, prior trials (cholestyramine, naltrexone, rifampin, or ursodiol), prescriber restricted to gastroenterology/hepatology, and reauthorization requires pruritus improvement and updated liver function testing.

    • Initial authorization requires failure/intolerance to at least two of: cholestyramine, naltrexone, rifampin, ursodiol.
    • First reauthorization: attestation of pruritus improvement and submission of liver function tests including bilirubin.
    Prior Authorization

    Caplacizumab — PA, prescriber and recurrence limits

    Caplacizumab prior authorization: age ≥12, prescriber restricted to cardiology/hematology/immunology, confirmation it will be given with plasma exchange and immunosuppression, coverage duration 3 months; if request is not first use, submit prior aTTP recurrence history (coverage not authorized if >2 recurrences while on therapy).

    • If not first use, coverage denied when >2 recurrences of aTTP while on caplacizumab.
    Prior Authorization

    CFTR modulators — mutation test required

    For CFTR modulators (Kalydeco, Orkambi, Symdeko, Trikafta) prior authorization requires submission of a CFTR mutation test confirming the drug-specific responsive mutation(s); prescriber restricted to pulmonology and coverage is for 1 year.

    • Trikafta: at least one mutation predicted to be responsive based on prescribing information or in vitro data.
    • Orkambi and Symdeko: F508del mutation requirements as specified.
    Prior Authorization

    PA — age/prescriber confirmation and 1-year duration

    Certain products require prior authorization with age and prescriber consistency and commonly have a 1‑year coverage duration; submit diagnosis and required supporting information per product.

    • Examples: many specialty drugs in this document require PA and annual coverage duration unless otherwise specified.
    Prior Authorization

    Dupilumab — PA, prerequisite therapy and reauthorization

    Dupilumab initial authorization is initially approved for 6 months then 1 year; providers must document and submit indication‑specific prior therapies (e.g., topical corticosteroid for AD; guideline-based triple inhaler for asthma; intranasal corticosteroid for CRSwNP) and attest continuation of required background therapy.

    • Reauthorization requires documentation of clinical benefit or maintenance of prior benefit; asthma/COPD reauthorization requires confirmation patient remains on triple inhaler therapy where specified.
    Prior Authorization

    GAVRETO — RET testing and oncology prescriber required

    GAVRETO prior authorization requires submission of RET gene fusion/mutation testing, prescriber restricted to oncology, age ≥12, and coverage duration 1 year.

    Prior Authorization

    PA — diagnosis confirmation and product-specific prerequisites

    Prior authorization is required with diagnosis confirmation and product‑specific age/prescriber consistency; coverage durations are typically 1 year unless otherwise specified.

    Prior Authorization

    KERENDIA — prior SGLT2 trial required and baseline labs

    KERENDIA initial authorization requires prior trial/failure or intolerance to an SGLT2 inhibitor (Farxiga or Jardiance); submit eGFR and baseline serum potassium as required.

    • Exclusions include adrenal insufficiency, eGFR <25 mL/min/1.73 m2, baseline serum potassium >5.0 mEq/L, severe hepatic impairment, or interacting drugs.
    Prior Authorization

    PA with 6‑month initial coverage — baseline labs required

    Certain products require PA with an initial coverage period of 6 months (then extension as specified); submit required medical information and baseline labs for the request.

    • Example: items listed with 6‑month initial duration in the document require baseline lab submission as part of PA.
    Prior Authorization

    Oncology PA — QTcF, electrolytes, mutation testing

    Some oncology drugs are restricted to oncology prescribers and require baseline QTcF and electrolytes (within the prior 6 months), tumor genetic testing as applicable, and have a 1‑year coverage duration.

    • Provider must submit QTcF interval, serum potassium and magnesium when specified.
    Prior Authorization

    PA — mutation testing and indication attestations

    Prior authorization for select agents requires submission of mutation testing (BRCA, HRR, etc.) and indication‑specific attestations (for example, response to platinum chemotherapy for some ovarian indications); coverage is typically 1 year.

    Prior Authorization

    PA — required diagnostic/lab data and prescriber specialty

    Prior authorization generally requires submission of diagnosis, specified laboratory tests or scores (e.g., Child‑Pugh), prescriber specialty restriction where applicable, and pregnancy status for females of childbearing potential.

    • Providers should include required baseline labs and specialty attestations specified per product.
    Prior Authorization

    Inbrija — off‑episode attestation and prior trials required

    Inbrija prior authorization requires attestation that the patient experiences 'off' episodes despite carbidopa/levodopa and prior trials/failures of at least two different medication classes (COMT inhibitors, dopamine agonists, MAO‑B inhibitors) unless contraindicated; annual reauthorization requires confirmation of symptomatic or clinical improvement.

    • Exclusions include recent non‑selective MAOI use within 14 days, asthma, COPD, or other chronic lung disease.
    Prior Authorization

    REPATHA — statin trial/intolerance and LDL threshold

    REPATHA prior authorization for certain indications requires documentation the patient failed to achieve LDL <70 mg/dL despite ≥8 weeks of high‑intensity statin therapy (or meets statin‑intolerance criteria); coverage duration 1 year.

    • Prescriber restriction: cardiology/endocrinology or lipid specialists.
    Prior Authorization

    REVUFORJ — diagnostic tests, baseline labs and exclusions

    REVUFORJ prior authorization requires submission of diagnostic testing confirming the KMT2A translocation (not 11q23 PTD) or absence of susceptible NPM1 mutation, baseline QTcF, serum potassium and magnesium, baseline WBC, pregnancy status; prescriber restricted to hematology/oncology and coverage duration 1 year.

    • Exclusions include QTcF >450 msec, WBC >25 x10^9/L, uncorrected hypokalemia or hypomagnesemia, and coadministration with moderate/strong CYP3A4 inducers.
    Prior Authorization

    Atypical antipsychotics — psychiatry prescriber and step therapy

    Atypical antipsychotics (e.g., Caplyta, Rexulti) require prior authorization with prescriber restricted to psychiatry, coverage duration 1 year, and specific step‑therapy requirements per Other Criteria.

    • Required documentation: current/previous therapies and trials/failures per indication.
    Prior Authorization

    SUNOSI — prior stimulant trial and specialty prescriber

    SUNOSI prior authorization requires prescriber be a neurologist or sleep medicine specialist; patient must have tried and failed armodafinil or modafinil for initial approval; coverage duration 1 year.

    Prior Authorization

    Urology‑restricted product — urologist prescriber and renal data

    Prior authorization for the listed urology‑restricted product requires the prescriber be a urologist and patient be ≥18 years; submit creatinine clearance (or data to calculate it) as part of the PA.

    Prior Authorization

    Cardiology‑restricted product — cardiologist prescriber and ATTR diagnostics

    PA for cardiology‑restricted products (e.g., transthyretin amyloid cardiomyopathy agents) requires prescriber be a cardiologist and patient be ≥18; submit diagnostic confirmation and coverage duration is typically 1 year.

    • For ATTR cardiomyopathy provide cardiac biopsy, immunohistochemistry, technetium‑99 SPECT/scintigraphy, or TTR genetic mutation plus cardiac involvement.
    Prior Authorization

    VERQUVO — HFrEF event, optimized therapy and cardiology prescriber required

    VERQUVO (oral tablets 10, 2.5, 5 mg) prior authorization: initial approval requires qualifying recent HFrEF event and optimized guideline‑directed therapy trials; prescriber restricted to cardiology and coverage duration 1 year.

    • Submit hospitalization for HFrEF within 6 months or outpatient IV diuretic use within 3 months, LVEF <45%, and current/previous HFrEF therapies.
    Prior Authorization

    HFrEF product — optimized therapy and documentation required

    HFrEF product prior authorization requires cardiology prescriber, patient ≥18, qualifying recent hospitalization or IV diuretic use and LVEF <45%; must be on optimized triple therapy (ACEi/ARB/sacubitril‑valsartan, beta‑blocker, MRA) or provide rationale for non‑use; coverage duration 1 year.

    Prior Authorization

    Verzenio — tumor testing and CYP interaction exclusions

    Verzenio prior authorization requires submission of tumor genetic testing confirming HR‑positive, HER2‑negative disease; exclusions include coadministration with moderate/strong CYP3A4 inducers or ketoconazole.

    Prior Authorization

    PIK3CA product — imaging, mutation test and specialist attestation

    PIK3CA‑targeted product prior authorization requires imaging demonstrating at least one target lesion, mutation testing confirming PIK3CA, provider attestation of severe or life‑threatening disease, specialist prescriber, and initial duration 6 months then 1 year with reauthorization requiring objective benefit documentation.

    Prior Authorization

    Vitrakvi — NTRK fusion evidence and oncology prescriber

    Vitrakvi (TRK fusion product) PA requires evidence of an NTRK gene fusion without known acquired resistance mutation, attestation tumor is metastatic or unresectable and other systemic therapies are unsatisfactory, prescriber restricted to oncology, coverage 1 year.

    Prior Authorization

    Voydeya — extravascular hemolysis criteria and hematology prescriber

    Voydeya initial authorization requires evidence of clinically significant extravascular hemolysis (Hgb ≤9.5 g/dL and absolute retic ≥120 x10^9/L) after use of a complement C5 inhibitor and concomitant use of eculizumab or ravulizumab; prescriber restricted to hematology; initial 6 months then 1 year.

    Prior Authorization

    VOYXACT — biopsy, proteinuria and prior therapy required

    VOYXACT (IgAN product) PA requires biopsy‑confirmed primary IgA nephropathy, 24‑hour urine protein ≥0.5 g/day or UPCR ≥0.8 g/g, and prior failure/intolerance to both a maximally tolerated ACE inhibitor or ARB and atrasentan or sparsentan; prescribers restricted to immunology/nephrology and coverage 1 year.

    Prior Authorization

    Wegovy — exclusions for weight management; MACE/MASH documentation required

    Wegovy PA: weight‑management use is excluded under Medicare Part D; for MACE indication require documentation of established cardiovascular disease and BMI ≥25 kg/m2, prescribers limited to cardiology/gastroenterology/hepatology/primary care; initial 32‑week induction then 1 year maintenance; for MASH require F2–F3 fibrosis confirmation and baseline/serial liver testing.

    • Provider attestations required (e.g., not using semaglutide for diabetes; not on another GLP‑1).
    Prior Authorization

    WINREVAIR — right heart cath data and regimen documentation

    WINREVAIR (PAH product) PA requires right heart catheterization results (mPAP >20 mm Hg, PAWP ≤15 mm Hg, PVR >2 WU), WHO Group 1 attestation, NYHA/WHO functional class II–IV, baseline platelet count, prescriber restricted to cardiology/pulmonology; initial 6 months then 1 year.

    • Regimen must include at minimum a nitric oxide pathway mediator and an endothelin receptor antagonist or documentation why not tolerated/used.
    Prior Authorization

    XIFAXAN — indication‑specific prior therapy and course limits

    Xifaxan PA: for hepatic encephalopathy (HE) prior lactulose trial failure/intolerance is required (coverage for HE: 1 year); IBS‑D requires failure of at least two medication classes; SIBO requires positive carbohydrate breath test and prior antibiotic trials; course limits apply (IBS‑D max three 14‑day courses lifetime; SIBO max two 14‑day courses per 365 days).

    • Documentation must include prior therapy dates and testing results as specified.
    Prior Authorization

    XOLAIR — prerequisite background therapy, testing and reauthorization

    Omalizumab (Xolair) PA for asthma requires patient be on a GINA‑recommended regimen (ICS + LABA + LAMA) at maximally tolerated doses with provider attestation it will be continued; CRSwNP and CSU require specified prior therapies/trial durations; reauthorization requires documented clinical benefit or maintenance of benefit; initial 6 months then 1 year.

    • Pre‑treatment testing (e.g., serum IgE, allergen testing, pre‑bronchodilator FEV1) is required per indication.
    Prior Authorization

    PA — document prior therapies and attestations

    PA requests must include documented prior therapies and indication‑specific attestations (e.g., continued background therapy, trial durations) as required by each product's Other Criteria; failure to document these prerequisites may result in denial.

    • Provider should submit specific prior therapy details, reasons for failure/intolerance, and diagnostic confirmation testing when required.
    Step Therapy

    Preferred‑agent step requirement — two preferred agent failures

    For many biologic and immunomodulatory agents, initial authorization generally requires failure of at least two preferred agents (adalimumab biosimilar, Cosentyx, Enbrel, Rinvoq, Skyrizi, ustekinumab biosimilar, Xeljanz) where feasible.

    Products listedmixed
    NUPLAZID ORAL CAPSULEproduct name
    NUPLAZID ORAL TABLET 10 MGproduct presentation
    Products listedmixed
    OGSIVEO ORAL TABLET 100 MG, 150 MG, 50 MGproduct presentations
    Products listedmixed
    INBRIJAproduct name
    apomorphine hcl subcutaneousproduct name
    Affected products (partial list)NDC/mixed
    REVUFORJ ORAL TABLET 110 MG, 160 MG, 25 MGProduct listing as affected medication
    Psychiatry productsmixed
    CAPLYTA ORAL CAPSULE 10.5 MG, 21 MG, 42 MGProduct listing
    REXULTI ORAL TABLET 0.25 MG - 4 MGProduct listing
    Products listed (no billing codes in this extract)mixed
    N/AThis extract lists product names rather than procedure or diagnosis codes; no explicit CPT/HCPCS/ICD-10 codes present in these chunks.
    Mean pulmonary arterial pressure
    Mean pulmonary arterial pressure (mPAP)> 20 mm Hg
    ContextRequired as part of right heart catheterization data for PAH PA requests
    UseSupports diagnosis of pulmonary arterial hypertension (WHO Group 1) per PA criteria
    Pulmonary arterial wedge pressure
    Pulmonary arterial wedge pressure (PAWP)<= 15 mm Hg
    ContextMeasured during right heart catheterization and required for PA/CTEPH PA requests
    InterpretationPAWP ≤15 mm Hg helps distinguish pre-capillary pulmonary hypertension (PAH) from post-capillary causes
    Pulmonary vascular resistance (PAH)
    Pulmonary vascular resistance (PAH)> 2 Woods units
    ContextDocumented for WHO Group 1 PAH in PA requests (right heart cath required)
    PurposeConfirms elevated pulmonary vascular resistance consistent with PAH
    Pulmonary vascular resistance (CTEPH)
    Pulmonary vascular resistance (CTEPH)> 3 Woods units
    ContextRequired for chronic thromboembolic pulmonary hypertension (WHO Group 4) PA requests along with imaging evidence of chronic PE
    ImplicationSupports diagnosis of CTEPH and need for specialist evaluation/management
    Platelet count (AYVAKIT advanced/indolent systemic mastocytosis exclusion)
    Platelet count threshold (AYVAKIT exclusion)< 50 x 10^9/L — exclusion
    ContextPatients with platelet count below this threshold are excluded from AYVAKIT use for advanced/indolent systemic mastocytosis per policy
    ActionDo not authorize AYVAKIT if platelet count <50 x 10^9/L; document recent lab results in PA submission
    LV outflow tract gradient
    LV outflow tract gradient>= 50 mm Hg
    ContextRequired confirmation for indicated cardiology product (LV outflow tract obstruction criteria) in PA requests
    DocumentationSubmit measurement at rest, Valsalva, or post-exercise as specified; include imaging/reporting source
    Left ventricular ejection fraction (CAMZYOS exclusion)
    Left ventricular ejection fraction (LVEF) exclusion< 55% — exclusion for CAMZYOS
    ContextAn LVEF below 55% is listed as an exclusion for the CAMZYOS entry; submit current LVEF with PA request
    ActionDo not authorize CAMZYOS if LVEF <55%; include echocardiogram/report in documentation
    RequirementDetails
    SGLT2 inhibitor prerequisite
    KERENDIA initial authorization requires the patient tried and failed to have an adequate response to or had intolerance/contraindication to an SGLT2 inhibitor (Farxiga or Jardiance).
    RequirementDetails
    PCSK9 inhibitor prerequisite
    For initial authorization of JUXTAPID in patients ≥10 years, the patient must have tried and failed to have an adequate response to or had intolerance/contraindication to evolocumab (a PCSK9 inhibitor).
    ScopeNote
    Step therapy applicability
    Yes — step therapy or prerequisite trials are required when specified for a given product; product‑specific Other Criteria detail which prior agents must be tried/failed.
    Documentation requirementDetails
    Prior trial documentation
    Prior trials as specified in the product's Other Criteria must be documented (drug names, dates, duration, reason for discontinuation — failure or intolerance) when submitting a PA request.
    RequirementDetails
    Inbrija prerequisite
    Initial Inbrija authorization requires attestation patient experiences 'off' episodes despite carbidopa/levodopa and prior trials/failures or intolerance to medications from at least two different classes (COMT inhibitors, dopamine agonists, MAO‑B inhibitors), unless contraindicated.
    RequirementDetails
    PIQRAY prerequisite therapy
    For PIQRAY, patient must have tried and failed at least one endocrine‑based regimen prior to initiation; genetic tumor testing confirming HR‑positive, HER2‑negative, and PIK3CA mutation must be submitted.
    RequirementDetails
    Required prior trials
    Certain agents require specified prior trials before approval — e.g., antipsychotic entries require failure/intolerance to specified generic atypical antipsychotics as detailed in Other Criteria.
    Patient groupStep requirement
    Older adults (≥65) — sedative‑hypnotics
    PA for sedative‑hypnotics applies only to patients age 65 or older and requires documentation that at least two alternatives (Belsomra, doxepin, ramelteon, trazodone) were tried and ineffective or intolerable.
    RequirementDetails
    Prior trial(s) required
    Some products require prior trials of specified agents or classes before approval (examples: parathyroid hormone analogs require prior bisphosphonate failure; vasomotor symptoms agents require failure/intolerance to at least two prior systemic hormone or non‑hormonal therapies from different classes).
    DocumentationDetails
    Document prior therapies and testing
    PA requests must document prior therapies, reasons for failure or intolerance, and any required diagnostic confirmation testing (e.g., biopsy, genetic testing, 24‑hour urine protein, breath test) as specified in the product's criteria.
    RequirementDetails
    Product‑specific prior therapy documentation
    Document prior therapies and failures per the product‑specific Other Criteria sections (for example, ZILBRYSQ requires failure of drugs in at least two of three classes; ZORYVE requires prior topical/systemic agents for plaque psoriasis).
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    DocumentationSubmit evidence of current use of one of these therapies with PA request (medication list or chart note)
    Prurigo nodularis (PN)
    Prurigo nodularis (PN) — diagnostic definitionPruritus lasting at least 6 weeks with pruriginous firm nodular lesions (documentation required for Dupixent requests)
    ContextUsed to establish eligibility for Dupixent in PN indication; include clinical description and duration in PA submission
    DocumentationProvide clinic notes and/or photographs describing nodular lesions and pruritus duration
    Responsive CFTR mutation
    Responsive CFTR mutation — definitionA CFTR gene mutation predicted to be responsive to a specific CFTR modulator based on prescribing information section 12.1 or in vitro data
    ContextRequired mutation confirmation for CFTR modulator PA (Kalydeco, Orkambi, Symdeko, Trikafta)
    DocumentationSubmit CFTR mutation test report specifying mutation(s) and citation to prescribing information where responsiveness is defined
    Eosinophilic esophagitis (EoE) diagnostic criterion
    EoE diagnostic histologyUpper endoscopy with biopsy showing ≥15 eosinophils per high-power field (or 60 eos/mm2) — required for EoE diagnosis
    ContextAlso require documentation of signs/symptoms (dysphagia, food impaction, reflux, pain) and PPI trial failure prior to PA
    AgePolicy specifies age ≥11 years for this indication where applicable
    Immune thrombocytopenia (ITP) threshold
    Immune thrombocytopenia (ITP) platelet thresholdsPlatelet count <30 x 10^9/L OR <50 x 10^9/L with increased bleeding risk; prior therapies tried/failed required
    ContextUsed to determine eligibility for thrombopoietic agents (eg eltrombopag, DOPTELET); submit recent platelet counts and prior therapy history
    DocumentationInclude splenectomy status and list of prior ITP therapies (systemic corticosteroids, IVIG, danazol, fostamatinib, cytotoxics/immunosuppressants)